🔗 Share this article

Given that America proceeds with sweeping revisions to its vaccine guidelines, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by questioning Covid vaccines throughout the pandemic and has focused upon possible deaths after Covid vaccination in her short time at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Program

Agency leaders had intended to unveil major changes to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of step with much of the global community with little proof for public health gain. The planned update has been pushed back until the new year.

In place of the top vaccines chief, Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the office this year.

Consolidating Power at the Agency

This interim role might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad consolidate power at the agency – and it points to a increased emphasis upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing specific pediatric shot schedules in the US in order to be more in line with the Danish model, a society with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – traditionally the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Background

The appointee has no obvious experience in drug development, approval processes or leadership, which has been standard for previous heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since March.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, said Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She is not an expert in industry regulation.”

Former commissioners of CBER would “grasp regulatory frameworks and the science of drug development”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that previous people who headed the center have had.”

CDER has an vast portfolio at the FDA, Woodcock stated.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office clears numerous generic drugs. There is also a biosimilars division, OTC medication office and so forth, and each of these need to be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a major management element to the role, which manages over 5,000 employees. “It is a huge management job, if you execute it properly,” the former official said.

Official Statement and Disputed Initiatives

When asked about concerns about Høeg’s credentials and whether this selection signifies increased cooperation among agency officials on vaccines, a representative stated that the “questions rely on flawed presumptions”.

“Her resume aligns with the functions of her position,” the official said, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that reportedly worried her preceding directors. “By what process are these medications being chosen for this voucher program? Who takes the decisions?” Dr. Howard asked. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed regulations of most medications, with the exception of vaccines.”

Documented History on Vaccines

Concerning immunizations, Høeg has a more established, if problematic, history, Howard observe. She released a study using non-validated public submissions to determine the rate of myocarditis following Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the new federal leadership featured revising regulations for recently developed shots and discontinuing “unnecessary” vaccines, she stated following the vote on a online show. At the agency, Høeg has allegedly floated the idea of excluding young men from getting Covid vaccines.

“She is an thorough true believer who begins with her conclusions and reverse-engineers to accommodate the science in a extremely disingenuous, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|